Grufity logo
Grufity logo
ATXS

ATXS - Astria Therapeutics, Inc. Stock Price, Fair Value and News

$12.58 
Market Closed as of 23 Jan 2026, 04:00 pm ET

Price Targets

ATXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATXS Price Action

Last 7 days

0.9%

Last 30 days

-3.1%

Last 90 days

1.1%

Trailing 12 Months

66.6%

ATXS RSI Chart

ATXS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ATXS Valuation

Market Cap

710.0M

Price/Earnings (Trailing)

-5.72

Price/Sales (Trailing)

1.4K

Price/Free Cashflow

-5.91

ATXS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

ATXS Fundamentals

ATXS Revenue

Rev. Growth (Yr)

106.92%

Rev. Growth (Qtr)

14.83%

ATXS Earnings

Earnings (TTM)

-124.0M

Earnings Growth (Yr)

-28.98%

Earnings Growth (Qtr)

4.26%

ATXS Profitability

Return on Equity

-53.17%

Return on Assets

-45.62%

Free Cashflow Yield

-16.91%

ATXS Investor Care

Dividend Yield

0%

Dividend/Share (TTM)

0

Shares Dilution (1Y)

1.61%

Diluted EPS (TTM)

-2.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2025----
2017---500.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Astria Therapeutics, Inc.

ATXS
Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
 CEO
 WEBSITEastriatx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES45

Astria Therapeutics, Inc. Frequently Asked Questions

ATXS is the stock ticker symbol of Astria Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jan 23 2026, market cap of Astria Therapeutics, Inc. is 709.95 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jan 23 2026, ATXS's PE ratio (Price to Earnings) is -5.72 and Price to Sales (PS) ratio is 1.42 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ATXS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Astria Therapeutics, Inc. has provided -0.289 (multiply by 100 for percentage) rate of return.